Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab

Magnetic Resonance in Medicine

Volumn 64, Issue 2, 2010, Pages 408-417

  Port, Ruediger E ^a   Bernstein, Lisa J ^a   Barboriak, Daniel P ^b   Xu, Lu ^a   Roberts, Timothy P L ^c   Van Bruggen, Nicholas ^a  

^a GENENTECH INC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Bevacizumab; DCE MRI; Gd DTPA; Glioblastoma; Impulse response function; Mean residence

Indexed keywords

BLOOD; IMPULSE RESPONSE; KINETICS; MAGNETIC RESONANCE IMAGING; RATE CONSTANTS;

BEVACIZUMAB; DCE-MRI; GD-DTPA; GLIOBLASTOMAS; IMPULSE RESPONSE FUNCTIONS; MEAN RESIDENCE;

TUMORS;

BEVACIZUMAB; GADOLINIUM PENTETATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR VOLUME;

EID: 77955101935     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22399     Document Type: Article

References (47)

1. O'Connor J, Jackson A, Parker G, Jayson G. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-195. (Pubitemid 46160619)
2. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee TY, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
3. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.
4. Leach M, Brindle K, Evelhoch J, Griffiths J, Horsman M, Jackson A, Jayson G, Judson I, Knopp M, Maxwell R, McIntyre D, Padhani A, Price P, Rathbone R, Rustin G, Tofts P, Tozer G, Vennart W, Waterton J, Williams S, Workman P. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-1610.
5. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPAimaging. JMagn Reson Imaging 1997;7:91-101.
6. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging, 1: fundamental concepts. Magn Reson Med 1991;17:357-367.
7. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPAin patients with multiple sclerosis and brain tumors. Magn Reson Med 1990;16:117-131.
8. Port RE, Knopp MV, Hoffman U, Milker-Zabel S, Brix G. Multi-compartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR Imaging. J Magn Reson Imaging 1999;10:233-241. (Pubitemid 29463105)
9. Port RE, Knopp MV, Brix G. Dynamic contrast-enhanced MRI using Gd-DTPA: Interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med 2001;45:1030-1038.
10. Luedemann L, Hamm B, Zimmer C. Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 2000;18:1201-1214. (Pubitemid 32121436)
11. Luedemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 2005;23:833-841. (Pubitemid 41579025)
12. Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion: approaches and biomedical challenges. IEEE Eng Med Biol 2004;23:65-83.
13. Fan X, Medved M, River JN, Zamora M, Corot C, Robert P, Bourrinet P, Lipton M, Culp RM, Karczmar1 GS. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med 2004;51:487-494.
14. Li X, Huang W, Morris EA, Tudorica LA, Seshan VE, Rooney WD, Tagge I, Wang Y, Xua J, Springer CS Jr. Dynamic NMR effects in breast cancer dynamic-contrast-enhanced MRI. Proc Natl Acad Sci USA 2008; 105:17937-17942.
15. Fan X, Karczmar GS. A new approach to analysis of the impulse response function IRF in dynamic contrast-enhanced MRI (DCEMRI): a simulation study. Magn Reson Med 2009;62:851-859.
16. Donaldson SB, West CM, Davidson SE, Carrington BM, Hutchison G, Sourbron SP, Buckley DL. The microvascular characteristics of cervical cancer: limitations of the modified-Tofts tracer kinetic model for the analysis of DCE-MRI data. Proc Intl Soc Mag Reson Med 17 2009; 17:2268.
17. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:612-628.
18. Brix G, Kiessling F, Lucht R, Darai S, Wasser K, Delorme S, Griebel J. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004;52:420-429. (Pubitemid 39025290)
19. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams & Wilkins; 1995, p. 601.
20. Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988; 16:475-492. (Pubitemid 19017475)
21. Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE. An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: Application to glioblastoma treated with bevacizumab. Magn Reson Med 2010;63:1366-1375.
22. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13:15-23. (Pubitemid 23016599)
23. Stakgold I. Green's functions and boundary value problems. New York: John Wiley & Sons; 1979, p. 712.
24. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokin Biopharm 1978;6:547-558.
25. Blüml S, Schad LR, Stepanow B, Lorenz WJ. Spin-lattice relaxation time measurements by means of a TurboFLASH technique.Magn Reson Med 1993;30:289-295.
26. Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000;12:347-357.
27. Blockley N, Jiang L, Gardener A, Ludman C, Francis S, Gowland P. Field strength dependence of R1 and R2* relaxivities of human whole blood to prohance, vasovist, and deoxyhemoglobin. Magn Reson Med 2008;60:1313-1320.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i: 307-310.
29. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJS, Bentzen S, Stirling JJ, Padhani AR. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-142.
30. Vredenburgh JJ, Desjardin A, Herndon II JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathomsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioblastoma. Clin Cancer Res 2007;13:1253-1259. (Pubitemid 46424067)
31. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vetek G, Palyka I, Springer CS Jr. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000;44:563-574.
32. Li X, Rooney WD, Springer CS Jr. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med 2005;54:1351-1359.
33. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain, I theoretical derivation. J Cereb Blood Flow Metab 1998;18:1365-1377.
34. Buckley DL, Roberts C, Parker GJM, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrastenhanced T1-weighted MR imaging initial experience. Radiology 2004;233:709-715.
35. Hassid Y, Eyal E, Margalit R, Furman-Haran E, Degani H. Non-invasive imaging of barriers to drug delivery in tumors. Microvasc Res 2008;76:94-103.
36. Cheng HL. Improved correlation to quantitative DCE-MRI pharmacokinetic parameters using a modified initial area under the uptake curve (mIAUC) approach. J Magn Reson Imaging 2009;30:864-872.
37. Roberts HC, Robert TPL, Bollen AW, Ley S, Brasch RC, Dillon WP. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001;8:384-391.
38. Barboriak D, DesJardins A, Rich J, Phadke D, Friedman H, Vredenburgh J. Treatment of recurrent glioblastoma multiforme with bevacizumab and irinotecan leads to rapid decreases in tumor plasma volume and ktrans, http://rsna2007. rsna.org/rsna2007/V2007/conference/ event-display.cfm?em-id=5010835.
39. Zhang W, Kreisl TN, Solomon J, Reynolds RC, Glen DR, Cox RW, Fine HA, Butman JA. Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. Proc Intl Soc Mag Reson Med 2009;17:282.
40. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-777.
41. O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MAT, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-6682.
42. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
43. Koukourakis MI, Mavanis I, Kouklakis G, Pitiakoudis M, Minopoulos G, Manolas C, Simopoulos C. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol 2007;30: 315-318.
44. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SCJ, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 2008;26:1316-1323.
45. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996;183:1981-1986. (Pubitemid 26158890)
46. Shames DM, Kuwatsuru R, Vexler V, Muehler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993;29:616-622. (Pubitemid 23138050)
47. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74. (Pubitemid 28365640)